Centessa pharmaceuticals announces poster presentation of phase 1 clinical data for orx750, a novel orexin receptor 2 (ox2r) agonist, at the american academy of neurology (aan) 2025 annual meeting

Boston and london, march 06, 2025 (globe newswire) -- centessa pharmaceuticals plc (nasdaq: cnta), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that data from the phase 1 clinical trial of orx750, an investigational novel highly potent and selective ox2r agonist being progressed for the treatment of narcolepsy type 1 (nt1), narcolepsy type 2 (nt2) and idiopathic hypersomnia (ih), will be presented in a poster session at the american academy of neurology (aan) 2025 annual meeting being held april 5-9, 2025, in san diego, ca. orx750 is being evaluated in an ongoing phase 2a clinical trial (crystal-1) in participants with nt1, nt2 and ih.
AAN Ratings Summary
AAN Quant Ranking